We propose to lead a presentation on the completed Paterson Building, a research laboratory development at The Christie Hospital in Manchester.
The realised project, handed over mid 2023, was commissioned by CRUK, The Christie NHS FT, and University of Manchester. IHP, the joint venture between VINCI Building and Sir Robert McAlpine and its supply chain partners, BDP, Arup and Imtech have realised a fantastic, state-of-the-art facility that is a world-class transformational cancer research facility.
The primary project objective was to create a collaborative ‘Team Science’ environment, which brings together scientific researchers and cancer care clinicians under one roof, co-located on the same campus. This alignment connects all stakeholders in the cancer care delivery system. The building is home to the largest concentration of scientists, clinicians and clinicians in Europe. 300 scientists and 400 clinicians and operational staff are now delivering clinical trials covering the full extent of the patient pathway, from prevention and novel treatments to living with and beyond cancer.
At 25,000m2 and ten storeys high, the building is more than twice the size of the previous facility, allowing experts to deliver discovery research and translate their findings into innovative clinical trials, at scale.
The building is occupied by all three of the partners. It’ll be home to the Cancer Research UK Manchester Institute, as well as several other teams from The University of Manchester’s Division of Cancer Sciences. It will also be Manchester’s scientific headquarters for discovery science within the international Alliance for Early Cancer Detection.
A central component of the building will be the new Cancer Research UK Cancer Biomarker Centre. The centre’s focus will be on biomarkers to aid in early cancer detection and diagnosis, and enable personalised management of a patient’s cancer, to determine which therapy will bring the most benefit.
The development provides a model for other providers to emulate and forms part of a wider, long-term strategy to constantly drive ‘bench to bedside’ cancer translation research to clinical trials.